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Abstract 
Background: Most people with stroke in India have no access to organised 
rehabilitation services. The effectiveness of training family members to provide 
stroke rehabilitation is uncertain. Our primary objective was to determine whether 
family-led stroke rehabilitation, initiated in hospital and continued at home, would be 
superior to usual care, in a low resource setting.   
Methods:  The Family-led Rehabilitation after Stroke in India (ATTEND) trial was a 
prospectively randomised open trial with blinded endpoints (PROBE) conducted 
across 14 hospitals in India. Patients (and their caregivers) were randomised to 
intervention or usual care by site coordinators, using a secure web-based system, 
with minimisation by site and stroke severity. The intervention group received 
additional structured rehabilitation training, commenced in hospital and continued at 
home for up to 2 months. The primary outcome was death or dependency, defined 
by scores 3 to 6 on the modified Rankin scale (range, 0 [no symptoms] to 6 [death]) 
as assessed by blinded observers at six months.  Secondary outcomes included any 
serious adverse event, hospital length of stay, activities of daily living, health-related 
quality of life, anxiety and depression, and caregiver strain. All analyses were 
intention to treat.  
Registration:  Clinical Trials Registry-India (CTRI/2013/04/003557); Australian New 
Zealand Clinical Trials Registry (ACTRN12613000078752); and Universal Trial 
Number (U1111-1138-6707) 
Findings:  A total of 1,250 patients were randomised (623 intervention and 627 
control) between 13 January 2014 and 12 February 2016. At six months, 285 of 607 
(47·0%) participants in the intervention group were dead or dependent compared to 
287 of 605 (47·4%) in the control group (odds ratio 0·98; 95% confidence Interval 
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0·78 to 1·23, P = 0·87). No significant differences were observed in any of the 
secondary or safety outcomes . 
Interpretation:  Family-led rehabilitation did not improve outcome after stroke unit 
admission.  
Funding: The National Health and Medical Research Council of Australia    
Abstract word count 307 (max 300)  
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Family-led rehabilitation after stroke in India: A Randomised Controlled Trial 
 
Stroke rates are rising in low- and middle-income countries (LMIC) but services are 
limited.1 Task shifting rehabilitation activities to unpaid caregivers may offer a 
sustainable alternative to conventional rehabilitation, and provide an affordable 
strategy in meeting the health demands in high and LMICs.2-5 India, with one sixth of 
the world’s population, only has approximately 35 stroke units, located mainly in 
urban centres.6,7 Consequently most people have no access to specialised stroke 
care and little access to conventional rehabilitation programs. Given that LMICs only 
have about 3% equivalent purchasing power to spend on healthcare compared to 
high-income countries, any new model of stroke rehabilitation should be both 
sustainable and effective.8,9 Our hypothesis was that family caregiver delivered 
rehabilitation would increase independence and survival after stroke unit admission. 
We report the results of the Family-led Rehabilitation after Stroke in India (ATTEND) 
trial, which evaluated a rehabilitation training program to deliver family-led 
rehabilitation after stroke.   
 
Methods 
Study design 
ATTEND was a prospectively randomised open trial with blinded endpoint (PROBE) 
conducted across 14 hospitals in India. Approvals were obtained from the ethics 
committees of the University of Sydney, Australia and at each participating hospital. 
Permission was also obtained from the Health Ministry Screening Committee, New 
Delhi. The protocol was published prior to unblinding.10 
Participants 
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Patients were eligible if they had an informal family or other caregiver who was 
willing to deliver rehabilitation, were aged 18 years or older, had a stroke within the 
past month, were able to be randomised within 7 days of admission to hospital, had 
residual disability (defined by needing help from another person for everyday 
activities) had a reasonable expectation of survival (i.e. not for palliative care, no 
evidence of widespread cancer), and would be available for follow-up for 6 months, 
and they and their caregiver provided consent. Site Coordinators screened all 
admitted stroke patients and obtained written informed consent from patients and 
caregivers. 
 
Randomisation and masking 
The trial funded full-time Stroke Coordinators (physiotherapists) and blinded 
assessors at each site. The stroke coordinator assessed patients for eligibility, 
consented them, and collected key baseline and demographic data prior to 
randomisation. The stroke coordinator was also responsible for training the patients 
and caregivers. Patients were randomised (1:1) to intervention or a usual care 
control group via a secure web-based central randomisation system with 
minimisation by site and stroke severity (National Institutes of Health Stroke Scale 
[NIHSS] scores <8 versus > 8). To address potential unblinding Stroke Coordinators 
were not permitted to treat other non-trial stroke patients or share an office with the 
blinded assessor. Coordinators were instructed to conduct training sessions in a 
private room or behind curtains. Assessors were kept unaware of the details of the 
trial intervention, including having separate training sessions at annual collaborator 
meetings. Any inadvertent unblinding at an assessment was recorded. 
Procedures 
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The family rehabilitation training intervention was delivered in addition to routine 
rehabilitation at each site. An international steering group developed the culturally 
specific intervention, piloted an early version,11 and incorporated features to ensure it 
could be affordable when scaled up. The intervention was designed to be delivered 
by a rehabilitation professional (coordinator), commenced in hospital and continued 
at home. It involved training family members to provide a simplified version of 
evidence-based rehabilitation,12-14 and included: comprehensive impairment and 
disability assessment by the coordinators; information provision; joint goal setting 
with the patient and caregiver for basic activities of daily living (ADL), extended 
activities of daily living (EADL), communication; caregiver training for limb 
positioning; encouragement of the practice of task-specific activities; and reminders 
to prepare the patient and carer for hospital discharge. After hospital discharge, the 
coordinator performed up to six home visits to assess progress, continue caregiver 
training activities and reset goals. The training was designed to occur for 
approximately one hour a day in hospital, for about three days, with the intention of 
expediting early supported discharge.10 There was a written intervention guide for 
the coordinators and an intervention manual for the patient and caregiver. To reduce 
potential contamination, the manual was given to participants on the first home visit 
to prevent access by control participants in hospital.11 In our trial sites, usual care 
consisted of some therapy during hospital stay, with post-discharge care varying 
from no therapy to limited out-patient therapy sessions.  
 
To ensure intervention fidelity across sites, coordinators were collectively trained at 
study initiation and annual collaborator meetings, supplemented by on-site training 
as required. Intervention training was led by physiotherapists from India and 
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Australia. Day-to-day support was provided by a clinical coordination team that 
included a neurologist and physiotherapist. A log of trial interventions was collected 
by the Stroke Coordinator for each participant for hospital and home visit activities. 
Intervention patients (with their caregivers) were encourage by the Stroke 
Coordinator to keep a daily log of rehabilitation activities for 30 days after discharge. 
 
Only the steering and management committee members and coordinators were 
aware of the details of the family rehabilitation training intervention (including the 
written guide).  
 
 
Outcomes 
The primary outcome was the proportion of patients who were dead or disabled at 
six months as defined by scores of 3-6 on the modified Rankin scale (mRS) The 
mRS is a global seven-level measure of functioning with scores of 0 to 2 
representing good outcome and functional independence, 3 to 5 representing 
increasing levels of disability, and 6 death.15 Events during the initial hospital stay 
were collected by the unblinded coordinators: all other outcomes, including the 
primary outcome, were assessed by trained blinded assessors who evaluated the 
patient and caregiver at home, or at the hospital, or by phone if a face-to-face visit 
was not possible. A secondary outcome was an ordinal ‘shift’ analysis of the full 
range of categories of the mRS. Other outcomes included the simple validated 
recovery and dependency questions,16 length of hospital stay, place of residence 
(whether the same as before stroke, Yes/No), the Barthel Index (BI) of ADL (on a 
scale of 0 to 100 with lower scores representing fewer activities),17 the Nottingham 
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EADL scale (on a scale of 0 to 66 with lower scores representing fewer activities),18 
quality of life measured by the World Health Organisation Quality of Life (WHOQOL-
BREF, with domains scored from 0 to 100 with lower scores representing lower 
quality of life)19 and the EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-
5D) which includes an overall health state (on a scale of 0 to 100, with lower scores 
representing lower quality of life),20 and patient anxiety and depression according to 
the Hospital Anxiety and Depression Scale subscales (HADS, with lower scores 
indicating fewer symptoms).21 Caregiver outcomes were the Caregiver Burden Scale 
(on a scale from 21 to 84, with lower scores representing less burden) and anxiety 
and depression on the HADS subscales.22 Adverse events, including a pre-specified 
list of those most frequent after stroke, were sought. These included deaths due to: 
the initial stroke; myocardial infarction; pneumonia; other vascular or non-vascular. 
Our pre-specified non-fatal events were: recurrent stroke; myocardial infarction; bony 
fracture; infection; or other. All outcomes were also assessed at 3 months. Patients 
and caregivers were given a health diary to record details of any re-hospitalisation, 
with details collected at each assessment.  
 
Statistical analysis 
Based on the Early Supported Discharge Stroke trials,13 where death or disability 
was 50% in controls, a sample size of 1,200 (600 per group) was estimated to 
provide 90% power (a 0·05) to detect a 21% relative risk reduction (10.5% absolute 
reduction) in death or disability in the intervention group with a 20% loss to follow-up. 
 
All analyses were according to the intention-to-treat principle, and all tests were two-
sided with a nominal level of significance of 5%. The primary analysis compared the 
 14 
proportion of patients who were dead or dependent (mRS 3 to 6) at 6 months between 
the intervention and usual care groups in an unadjusted logistic regression model. 
Sensitivity analyses included adjustment for study site, stroke severity, age, sex, 
household income and patient level of education. Eight pre-specified subgroup 
analyses (age, stroke severity, stroke pathology, stroke Oxfordshire Community 
Stroke Project Classification, carer type, education level, household income and type 
of accommodation were performed by adding the subgroup variable as well as its 
interaction term, with the intervention as fixed effects to the logistic regression model 
used for the primary analysis. Sex had been inadvertently omitted (due to author error) 
in the statistical analysis plan and is also included for completeness.23 Other analyses 
included all 7 categories of the mRS using ordinal logistic regression and a 
permutation test proposed by Howard et al.24 Analyses of secondary outcomes at 3 
and 6 months used t-tests to compare means (e.g. mean BI score) and chi-square 
tests to compare proportions (e.g. place of residence). Length of hospital stay was 
analysed using a log-rank test and serious adverse events using Fisher’s Exact test. 
Further details are available in the Statistical Analysis Plan which was finalised and 
submitted for publication before unblinding.25 All analyses were conducted using SAS 
Enterprise Guide version 7·1 (SAS/Stat version 9·4). An independent Data and Safety 
Management Committee monitored the unblinded accumulating results and adverse 
events according to a written charter. 
The trial was registered at the Clinical Trials Registry-India (CTRI/2013/04/003557); 
the Australian New Zealand Clinical Trials Registry (ACTRN12613000078752); and 
has a Universal Trial Number (U1111-1138-6707). 
 
Trial Management 
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The trial was funded by the National Health and Medical Research Council of 
Australia with overall management of the study coordinated from The George 
Institute for Global Health, Sydney, Australia. Weekly teleconferences were 
undertaken between study personnel in Sydney and India during the preparation, 
conduct, and close-out of the trial. The national clinical coordination centre was 
based in Ludhiana, Punjab, India and project management was based at The 
George Institute India, Hyderabad, Telangana, India. The Indian Institute of Public 
Health, Hyderabad, Telangana provided independent trial monitoring. Additional 
logic checks and central monitoring of data were performed. The trial methods were 
piloted in Ludhiana11 and the protocol was published.10 The steering committee 
designed the study, collected the data (in collaboration with the hospital sites), made 
the decision to submit the manuscript for publication and vouch for the fidelity of the 
study to the protocol. The writing committee wrote the manuscript and vouch for the 
completeness and accuracy of the data and analyses. The George Institute for 
Global Health was responsible for analysis of the data.  
 
Role of the funding source 
The National Health and Medical Research Council had no role in study design, data 
collection, data analysis, data interpretation, or writing of the report. The 
corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication. 
 
Results 
A total of 1,250 participants were randomised between 13 January 2014 and 12 
February 2016. The flow of participants is shown in Figure 1. Baseline characteristics 
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are shown in Table 1. At hospital discharge there was no difference in mRS scores 
between intervention and control (90·4% dead or dependent in both, P= 0·96), nor of 
the BI (43·0 in intervention, 43·2 in control, P = 0·88) (Table 1S).  
 
The training program was delivered as planned with a mean (standard deviation) 
time of 3·0 (1·6) hours (median 2·9) in hospital. An additional 3·1 (1·7) hours 
(median 2·8) of training was delivered during home visits. Intervention patients and 
caregivers reported 17·8 hours (21·6) of rehabilitation performed in the first 30 days 
following hospital discharge (data available from 574 participants). Details of the 
rehabilitation provided to both groups as part of routine care, and the intervention are 
shown in Table 2S. There was no evidence of a difference in total routine hospital 
rehabilitation time (2·0 hours for intervention, 2·1 hours for control patients, P=0·23), 
although intervention participants practised fewer mobility activities than control 
participants (83·6% intervention versus 88·2% control, P=0·023). There were no 
statistical differences in other non-trial routine rehabilitation activities (Table 2S).  
 
At six months 285/607 (47·0%) participants were dead or disabled in the intervention 
group compared to 287/605 (47·4%) in the control group, odds ratio 0·98 (95% 
confidence interval [CI] 0·78 to 1·23, P = 0·87) (Table 3). The neutral results were 
similar in adjusted analyses and across all secondary outcomes (Tables 3 and 4, 
Table 2S). The mean (SD) number of days from randomisation to hospital discharge 
was 6·0 (6·8) in the intervention group and 6·3 (7·5) in the control group (P = 0·65). 
The intervention did not reduce total length of stay (mean [SD] stay of 9·3 [7·4] days 
in the intervention group versus 9·5 [7·9] days for control (P = 0·58) (Table 1S). 
There were no significant differences in non-fatal or fatal adverse events (Table 5), 
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with 72 (11·9%) deaths in the intervention group compared with 86 (14·2%) in the 
control (P = 0·23). In the intervention group, there were 9 deaths due to the initial 
stroke and 18 in controls (P = 0·08). There was no between group difference in 
caregiver strain, nor in anxiety or depression on the HADS. We documented 
unblinding in 5·3% of intervention patients and 3·3% of control patients (P=0·09). 
 
There was one significant interaction on the pre-specified subgroup analysis, by sex, 
where there were reduced odds of death or dependency in men at six months (odds 
ratio 0·83, 95% CI 0·63 to 1·10 versus odds ratio 1·39, 95% CI 0·93 to 2·05 for 
women, P=0·04 for interaction) (Figure 2). 
 
Discussion 
Our study showed that the addition of family-led rehabilitation training to usual stroke 
unit care did not decrease death or disability at six months, nor was there any benefit 
noted at the three-month assessment. In addition, the training did not influence any 
of the other physical, emotional or quality of life outcomes. The intervention was 
safe, with an observed non-significant reduction in deaths, and no increase in 
caregiver burden. The training was delivered as planned with a mean of 3·0 (median 
2·9) hours of hospital training and a mean of 3·1 hours (median 2·8) of community-
based training, with components consistent with the trial intervention guide. In the 
context of these Indian stroke units, where patients only received a total of two hours 
of therapy, the intervention more than doubled the amount of hospital rehabilitation 
and provided additional community caregiver and patient training. In the intervention 
group, 30 minutes of daily reported rehabilitation activities were reported by the 
patient and caregivers in the month after discharge.  
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The ATTEND intervention failed to decrease hospital length of stay. When our 
results are viewed in the context of the systematic review of early supported 
discharge after stroke13 (see Research in context), it can be seen that interventions 
without coordination from a dedicated multidisciplinary team currently lack evidence 
of benefit. We also note that the recently reported smaller RECOVER trial of nurse-
delivered rehabilitation after stroke in China was negative (R Lindley, personal 
communication). 
 
Our results are also consistent with the lack of benefit seen in a recent systematic 
review of trials of caregiver-mediated exercises to improve activities of daily living.26 
In this overview, the authors noted that there were few data (only 333 patients 
included in the six trials analysed), and that the quality of evidence was low- to 
moderate. Whilst the ATTEND intervention emphasised caregiver-mediated 
exercises, these were not the only component of the intervention.  
 
 
The lack of benefit of the family-rehabilitation intervention has important implications 
for stroke recovery research, behavioural change, and task shifting in general. Our 
training program may not have been sufficient (in time and content) to deliver 
effective family rehabilitation, as we only observed about 30 minutes of daily 
activities in the intervention group. Conventional western rehabilitation is usually 
associated with greater daily therapy time (1-2 hours).27 The training of family 
members was designed to be sustainable, and if family members required more 
training to meet the needs of their family patient, then the aspiration of routinely 
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providing rehabilitation through task shifting to family caregivers may not be feasible. 
Family dynamics may also limit the effectiveness of this strategy, and task shifting to 
a non-family generic health worker, such as the established Indian Accredited Social 
Health Activist (ASHA), may have been a more effective strategy, although likely 
more expensive. Technology assisted rehabilitation may also be another option of 
“task-shifting” that is the subject of current trials.28 
 
The lack of benefit may also have been due to individual training components being 
ineffective in changing behaviour. This possibility was raised by another trial, 
undertaken in the United Kingdom, where caregiver training (part of our intervention) 
was ineffective in the acute setting.29 As we were aware of these results before 
commencing our study, emphasis was also placed on the importance of continuing 
caregiver training after hospital discharge. The comprehensive nature of our 
intervention may have diluted the impact of individual components, and this lack of 
focus, for example, too much time spent on information provision, may have been at 
the expense of training task-specific mobility exercises.  
 
Although our primary outcome was not significant, the sample size may still have 
been insufficient to detect a more modest treatment effect. However, the consistency 
of results across all health dimensions provides support for the overall neutral effect. 
The main qualitative differences between conventional rehabilitation in high income 
countries, compared to our family rehabilitation intervention, are in the professional 
multidisciplinary structure and frequent review meetings. Our results suggest that the 
lower dose of family rehabilitation training, delivered by a single professional, whilst 
based upon evidence-based components across multiple disciplines, is an ineffective 
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model of care. Given our trial was performed at stroke units around India, our 
findings have not ruled out the possibility that the intervention could offer benefits in 
non-specialised hospitals, especially in rural and remote settings.  
 
The unexpected interaction with sex, with the observed improved outcome in men 
compared with women, may be due to the play of chance and requires further 
analysis. However, in Indian society, there may be important sex differences in the 
receipt and provision of a complex intervention such as ours. Our process evaluation 
aims to explore this, and other aspects of the trial, in more detail.30 
 
Strengths of our study include the piloting and development of a structured 
intervention supported by written materials and use of robust trial methods to 
address priorities set out in the WHO/World Bank World Report on Disability.9 Our 
funding provided sufficient resources to address the research question 
comprehensively and has contributed to building stroke research capacity across 
India. Our trial data are consistent with epidemiological evidence that stroke is 
affecting people in India about 15 years younger than those in high-income 
countries, highlighting the public health importance of improving global rehabilitation 
services, especially given that many of our participants were still working.31 
However, there are limitations given that our participants were generally from urban 
centres with higher than average education and income, thus potentially limiting the 
generalisability of these results to other areas of the country without any 
rehabilitation.   
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Task shifting is an attractive solution for healthcare sustainability.4,32,33 However, in 
none of 22 recommendations of the WHO Task Shifting Guidelines was there 
reference to evidence generation on effectiveness, despite acknowledgement their 
implementation should be accompanied by rigorous evaluation.4 Our evaluation of 
training the patient and family caregiver showed that this particular model of 
rehabilitation was ineffective. Our results illustrate that task shifting away from 
conventional rehabilitation, without rigorous evaluation, could waste limited 
resources. Our neutral results will be further interrogated through a process 
evaluation which will examine the social and economic influences on the behaviour 
of carers and patients. In addition, our results suggest that future research in this 
area should incorporate more behavioural change theory and evidence, when 
developing a new intervention. However, ATTEND was developed from the evidence 
base current at the time and focused on pragmatic practical solutions. 
 
In summary, our trial of family-led stroke rehabilitation was ineffective at improving 
health outcomes across a wide variety of dimensions. Alternative models of care to 
improve stroke recovery are required, especially those for the populations of LMICs 
where the burden of stroke is enormous.  
 
 
Main text word count 3565  
Panel: Research in context 
In low and middle income countries, community rehabilitation is seen as a high 
priority for health care delivery to reduce disability. Systematic reviews of early 
supported discharge (ESD) stroke services have shown this model of care reduces 
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death or dependency without adverse effects on family caregivers. We updated the 
search strategy (to January 2017) for the Cochrane review of ESD services (services 
for reducing the duration of hospital care for acute stroke patients) that categorises 
interventions into those with or without coordinated multidisciplinary team input. We 
identified two similar RCTs (n=289) in the latter category that tested a similar 
intervention; ATTEND pilot study; and an unpublished Chinese trial of nurse-
delivered rehabilitation after stroke. 
Added value of this study 
This is the first large RCT to test task shifting of stroke rehabilitation to family 
members. This approach did not improve outcome (compared to usual care) after 
stroke unit admission. The results were consistent with previous smaller RCTs of 
ESD services without multidisciplinary team coordination. 
Implications of all the available evidence 
Family-led rehabilitation does not improve outcomes, but did not increase harms 
such as increased burden of care for the family. These results do not support 
investing in new stroke rehabilitation services that shift tasks to family caregivers. 
Future models of low-cost stroke rehabilitation should investigate task shifting to 
non-family workers or team based community care.  
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Legends 
 
Figure 1: Trial profile 
 
Table 1: Baseline characteristics 
Notes for Table 1 
Data are N (%) unless indicated otherwise 
*Data complete for sex and age, One patient withdrew after randomization and 
denominator is 622 for other baseline variables in the intervention group 
† INR Household income in Indian rupees (INR) per month 
USA$1 = 68INR 
‡ OCSP: Oxfordshire Community Stroke Project Stroke Classification for those with 
ischaemic stroke 
§ NIHSS: National Institutes of Health Stroke Scale 
||  Percentage only shown as denominator varies due to missing data  
 
 
Table 2: Analysis of mRS 
Notes for Table 3 
* Sensitivity analyses included adjustment for study site, stroke severity, age, sex, 
household income and patient level of education. The P-value from the likelihood 
ratio test of the logistic regression 
†  Adjusted analysis includes the following covariates: study site, stroke severity 
(NIHSS Score < 8 or >=8), age (as a continuous variable), sex, income (<5000, 
5000-<15000, 15000-<30000, 30000 and more, no answer/missing) and education 
(college/university/postgraduate, high school, primary/secondary/less than primary 
school, no schooling/missing) 
‡ Primary outcome 
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§ Ordinal analysis performed using proportional odds logistic regression  
Figure 3 
Patients achieving each mRS score at 6 months 
mRS = modified Rankin Scale 
 
Table 3: Analysis of secondary outcomes at Month 3 and Month 6 
 
Table 4 Notes 
* P-value by Chi-square test 
† P-value by Chi-square test only performed on “same as before stroke” versus 
“other” 
‡ P-value by t-test 
 
Figure 3: Main subgroup analyses 
*NIHSS: National Institutes of Health Stroke Scale 
†OCSP: Oxfordshire Community Stroke Project Stroke Classification 
‡Level of education for patient 
§Household income in Indian rupees (INR) per month 
USA$1 = 68INR  
 
Table 1S: Hospital discharge information 
Table 1S Notes 
* P-value by Log-rank test 
† P-value by t-testT 
‡ P-value by Chi-square test 
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Table 2S: Routine and intervention therapy 
Notes for Table 2S 
* P-value by t-test 
† Total number of sessions 
‡ Number and proportion of patients with at least one activity 
§ P-value by Fisher’s exact test 
 
Table 3S: Distribution of categories on the modified Rankin scale (mRS) 
between intervention and control using the assumption-free statistical method 
of Howard 
Table 3S Notes 
 
*Howard G, Waller JL, Voeks JH, et al. A simple, assumption-free, and clinical interpretable 
approach for analysis of modified Rankin outcomes. Stroke 2012;43:664-669.  
 
The assumption-free approach considers all possible pairs of observations where the first 
observation is taken from the Intervention group (YT) and the second observation is taken 
from the Control group YC. If group YT included n observations and group included m 
observations, the two-group comparison would lead to the total of n x m pairs of 
observations. In each pair, the observation from the treatment group will either be worse 
than the control observation, the same as the control observation, or better than the 
control observation. The probabilities that in a randomly chosen pair of treatment and 
control patients, the treatment patients has worse outcome (Prob (YT > YC)), the same 
outcome (Prob (YT + YC)) or better outcome (Prob (YT < YC)), can then be estimated as the 
ratio of the number of pairs satisfying each of these individual conditions to the total 
number of n x m pairs.  
The permutation test first calculates a ‘test statistic’ for the observed data. In our study, we 
tested how far the observed proportion of non-tied pairs was from the null-hypothesis of 
50%. The permutation test randomly assigned treatments to individuals, ensuring no 
association between treatment and the test statistic (guaranteeing the null hypothesis is 
true). This process was repeated 10,000 times, and the distribution of the test statistic 
under the null hypothesis was estimated. Whether the observed test statistic is unusual 
under the null hypothesis (that is, the P value) is simply the location of the observed test 
statistic in distribution of test statistics under the null hypothesis.  
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Table 4S Notes 
* Fisher’s exact test comparing the proportion of patients with at least one event 
† Total number of events (one patient can contribute more than one event)  
 
 
 
* 
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Table 1: Baseline characteristics 
 
Socio-demographic characteristics 
Intervention 
(N=623) 
Control 
(N=627) 
Total 
(N=1250) 
Sex    
   Male 421 (67·6%) 416 (66·3%) 837 (67·0%) 
   Female 202 (32·4%) 211 (33·7%) 413 (33·0%) 
    
Age (years)    
   N   Mean (SD) 623   57·5 (12·92) 627   58·0 (14·21) 1250   57·7 (13·58) 
   Median (interquartile range) 58 (50 to  66) 59 (49 to 67) 59  (50 to 66) 
   min   max 18   95 19   95 18   95 
   18 - <40 58 (9·3%) 63 (10·0%) 121 (9·7%) 
   40 - <50 89 (14·3%) 97 (15·5%) 186 (14·9%) 
   50 - <60 189 (30·3%) 159 (25·4%) 348 (27·8%) 
   60 - <70 175 (28·1%) 176 (28·1%) 351 (28·1%) 
   70 - <80 89 (14·3%) 89 (14·2%) 178 (14·2%) 
   >=80 23 (3·7%) 43 (6·9%) 66 (5·3%) 
    
Marital status*    
   Married 563 (90·5%) 557 (88·8%) 1120 (89·7%) 
   Unmarried 16 (2·6%) 18 (2·9%) 34 (2·7%) 
   Separated 2 (0·3%) 1 (0·2%) 3 (0·2%) 
   Widowed 41 (6·6%) 51 (8·1%) 92 (7·4%) 
    
Main caregiver    
   Spouse 257 (41·3%) 261 (41·6%) 518 (41·5%) 
   Mother 14 (2·3%) 11 (1·8%) 25 (2·0%) 
   Father 3 (0·5%) 6 (1·0%) 9 (0·7%) 
   Grandfather and Others 2 (0·3%) 2 (0·3%) 4 (0·3%) 
   Daughter / Daughter in law 151 (24·3%) 125 (19·9%) 276 (22·1%) 
   Son / Son in law 171 (27·5%) 192 (30·6%) 363 (29·1%) 
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Socio-demographic characteristics 
Intervention 
(N=623) 
Control 
(N=627) 
Total 
(N=1250) 
   Sister 3 (0·5%) 8 (1·3%) 11 (0·9%) 
   Brother 17 (2·7%) 19 (3·0%) 36 (2·9%) 
   Hired Help / nurse 4 (0·6%) 3 (0·5%) 7 (0·6%) 
    
Highest level of education completed (patient)    
   No schooling 88 (14·1%) 96 (15·3%) 184 (14·7%) 
   Less than primary school 58 (9·3%) 65 (10·4%) 123 (9·8%) 
   Primary school completed 113 (18·2%) 106 (16·9%) 219 (17·5%) 
   Secondary school completed 68 (10·9%) 57 (9·1%) 125 (10·0%) 
   High school completed 123 (19·8%) 142 (22·6%) 265 (21·2%) 
   College/university completed 142 (22·8%) 140 (22·3%) 282 (22·6%) 
   Postgraduate degree 29 (4·7%) 21 (3·3%) 50 (4·0%) 
   Unknown 1 (0·2%) 0 (0·0%) 1 (0·1%) 
    
Work status (patient)    
   Management 4 (0·6%) 7 (1·1%) 11 (0·9%) 
   Professional and related 22 (3·5%) 19 (3·0%) 41 (3·3%) 
   Service 85 (13·7%) 75 (12·0%) 160 (12·8%) 
   Sales / Commercial 64 (10·3%) 57 (9·1%) 121 (9·7%) 
   Construction 27 (4·3%) 29 (4·6%) 56 (4·5%) 
   Armed Forces 7 (1·1%) 9 (1·4%) 16 (1·3%) 
   Farming/ forestry/ fishing and related 60 (9·6%) 65 (10·4%) 125 (10·0%) 
   Clerical/ administrative support 21 (3·4%) 14 (2·2%) 35 (2·8%) 
   Installation and related 8 (1·3%) 4 (0·6%) 12 (1·0%) 
   Manufacture/ production 16 (2·6%) 21 (3·3%) 37 (3·0%) 
   Transportation/ driver 25 (4·0%) 27 (4·3%) 52 (4·2%) 
   Housewife 181 (29·1%) 186 (29·7%) 367 (29·4%) 
   Not Applicable 102 (16·4%) 114 (18·2%) 216 (17·3%) 
    
Work situation (patient)    
   Full time paid work 224 (36·0%) 186 (29·7%) 410 (32·8%) 
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Socio-demographic characteristics 
Intervention 
(N=623) 
Control 
(N=627) 
Total 
(N=1250) 
   Part time paid work 46 (7·4%) 50 (8·0%) 96 (7·7%) 
   Retired 96 (15·4%) 111 (17·7%) 207 (16·6%) 
   Unemployed 47 (7·6%) 31 (4·9%) 78 (6·2%) 
   Home duties 171 (27·5%) 203 (32·4%) 374 (29·9%) 
   Student 3 (0·5%) 3 (0·5%) 6 (0·5%) 
   Others 35 (5·6%) 43 (6·9%) 78 (6·2%) 
    
Accommodation details    
   Own house 501 (80·5%) 498 (79·4%) 999 (80·0%) 
   Own apartment/ flat 19 (3·1%) 26 (4·1%) 45 (3·6%) 
   Rented flat 37 (5·9%) 36 (5·7%) 73 (5·8%) 
   Rented accommodation in a house 42 (6·8%) 47 (7·5%) 89 (7·1%) 
   Government/ company provided house 22 (3·5%) 17 (2·7%) 39 (3·1%) 
   Jhuggi (slum) 0 (0·0%) 1 (0·2%) 1 (0·1%) 
   Others 1 (0·2%) 2 (0·3%) 3 (0·2%) 
    
Living situation pre-stroke    
   Independent at home 616 (99·0%) 610 (97·3%) 1226 (98·2%) 
   Dependent at home 6 (1·0%) 12 (1·9%) 18 (1·4%) 
   Others 0 (0·0%) 5 (0·8%) 5 (0·4%) 
    
Financial situation    
   Patient / his close family owns the house 507 (81·5%) 508 (81·0%) 1015 (81·3%) 
   Patient / his close family owns the flat 18 (2·9%) 20 (3·2%) 38 (3·0%) 
   Rented from landlord 77 (12·4%) 83 (13·2%) 160 (12·8%) 
   Government owned / allocated housing 20 (3·2%) 16 (2·6%) 36 (2·9%) 
    
Monthly Household income (INR) †    
   < 5000 93 (15·0%) 101 (16·1%) 194 (15·5%) 
   5000-14,999 178 (28·6%) 196 (31·3%) 374 (29·9%) 
   15,000-29,999 166 (26·7%) 151 (24·1%) 317 (25·4%) 
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Socio-demographic characteristics 
Intervention 
(N=623) 
Control 
(N=627) 
Total 
(N=1250) 
   30,000-59,999 99 (15·9%) 74 (11·8%) 173 (13·9%) 
   60,000-100,000 18 (2·9%) 20 (3·2%) 38/ (3·0%) 
   More than 100,000 8 (1·3%) 12 (1·9%) 20 (1·6%) 
   Decline to answer 39 (6·3%) 43 (6·9%) 82 (6·6%) 
   Don't know 21 (3·4%) 30 (4·8%) 51 (4·1%) 
    
Time from stroke onset to randomisation (days)    
   N   Mean (SD) 623   4·9 (3·8) 627   5·1 (4·1) 1250   5·0 (4·1) 
   Median (interquartile range) 4 (3 to 6) 4 (2 to 6)  4 (3 to 6) 
   min   max 0   28 0   29 0   29 
    
Stroke type    
   Ischaemic 478 (76·8%) 478 (76·2%) 956 (76·5%) 
      Large artery atherosclerosis 214 (44·8%) 213 (44·7%) 427 (44·7%) 
      Cardio embolism 75 (15·7%) 54 (11·3%) 129 (13·5%) 
      Small artery occlusion 113 (23·6%) 131 (27·5%) 244 (25·5%) 
   Determined, other etiology 16 (3·3%) 21 (4·4%) 37 (3·9%) 
   Undetermined 60 (12·6%) 58 (12·2%) 118 (12·4%) 
   Intracerebral haemorrhage 143 (23·0%) 148 (23·6%) 291 (23·3%) 
   Unspecified 1 (0·2%) 1 (0·2%) 2 (0·2%) 
    
OCSP classification‡    
   Total anterior circulation syndrome 67 (14·0%) 51 (10·7%) 118 (12·4%) 
   Partial anterior circulation syndrome 263 (55·0%) 269 (56·4%) 532 (55·7%) 
   Posterior circulation syndrome 72 (15·1%) 76 (15·9%) 148 (15·5%) 
   Lacunar syndromes 76 (15·9%) 81 (17·0%) 157 (16·4%) 
    
NIHSS score§    
   N   Mean (SD) 622   10·1 (4·9) 627   9·6 (4·8) 1249   9·9 (4·9) 
   Median (interquartile range) 9 (6 to 13)   9  (6 to 12)   9  (6 to 13) 
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Socio-demographic characteristics 
Intervention 
(N=623) 
Control 
(N=627) 
Total 
(N=1250) 
   min   max 1   29 1   28 1   29 
   0 - <5 72 (11·6) 103 (16·4) 175 (14·0) 
   5 - <10 247 (39·7) 241 (38·4) 488 (39·1) 
   10 - <15 188 (30·2) 182 (29·0) 370 (29·6) 
   >=15 115 (18·5) 101 (16·1) 216 (17·3) 
    
Medical history|| 
 
   
   Hypertension 73·6% 74·2% 73·9% 
   Diabetes Mellitus 44·7% 43·2% 43·9% 
   Dyslipidaemia 22·2% 24·6% 23·4% 
   Atrial fibrillation 7·9% 7·5% 7·7% 
   Coronary artery disease 15·6% 16·2% 15·9% 
   Obesity 15·3% 15·6% 15·5% 
   Smoking 25·6% 23·0% 24·3% 
   Alcohol use 26·5% 27·2% 26·8% 
   Drug addiction 0·6% 0·2% 0·4% 
   Carotid stenosis 19·9% 18·5% 19·2% 
   Previous stroke/TIA 17·9% 18·2% 18·0% 
   Rheumatic heart disease 3·4% 3·6% 3·5% 
   Neoplastic disease 0·5% 0·6% 0·6% 
   Pregnancy 0·0% 0·3% 0·2% 
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Table 2: Analysis of mRS 
 
Outcome 
Intervention 
(N=623) 
Usual care 
(N=627) 
Total 
(N=1250) 
Odds 
Ratio 
95%  
Confidence intervals p-value* 
 n/N (%) n/N (%) n/N (%)  
Primary outcome 
Death or disability (mRS score 3 to 6) 
       
  Month 6 (Unadjusted) ‡  285/ 607 (47·0) 287/ 605 (47·4) 572/1212 (47·2) 0·98 0·78 1·23 0·87 
 
Death or disability (mRS score 3 to 6) 
       
  Month 3 (Unadjusted) 336/ 600 (56·0) 337/ 593 (56·8) 673/1193 (56·4) 0·97 0·77 1·22 0·77 
  Month 3 (Adjusted) † 335/ 599 (55·9) 337/ 593 (56·8) 672/1192 (56·4) 1·00 0·77 1·29 0·99 
  Month 6 (Adjusted) 284/ 606 (46·9) 287/ 605 (47·4) 571/1211 (47·2) 1·02 0·80 1·31 0·87 
Ordinal analysis§        
  Month 3 (Unadjusted)        
    0 23/ 600 (3·8) 27/ 593 (4·6) 50/1193 (4·2) 0·92 0·75 1·12 0·42 
    1 147/ 600 (24·5) 130/ 593 (21·9) 277/1193 (23·2)     
    2 94/ 600 (15·7) 99/ 593 (16·7) 193/1193 (16·2)     
    3 141/ 600 (23·5) 133/ 593 (22·4) 274/1193 (23·0)     
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Outcome 
Intervention 
(N=623) 
Usual care 
(N=627) 
Total 
(N=1250) 
Odds 
Ratio 
95%  
Confidence intervals p-value* 
 n/N (%) n/N (%) n/N (%)  
    4 116/ 600 (19·3) 107/ 593 (18·0) 223/1193 (18·7)     
    5 22/ 600 (3·7) 30/ 593 (5·1) 52/1193 (4·4)     
    6 57/ 600 (9·5) 67/ 593 (11·3) 124/1193 (10·4)     
  Month 3 (Adjusted)        
    0 23/ 599 (3·8) 27/ 593 (4·6) 50/1192 (4·2) 0·94 0·76 1·15 0·52 
    1 147/ 599 (24·5) 130/ 593 (21·9) 277/1192 (23·2)     
    2 94/ 599 (15·7) 99/ 593 (16·7) 193/1192 (16·2)     
    3 141/ 599 (23·5) 133/ 593 (22·4) 274/1192 (23·0)     
    4 115/ 599 (19·2) 107/ 593 (18·0) 222/1192 (18·6)     
    5 22/ 599 (3·7) 30/ 593 (5·1) 52/1192 (4·4)     
    6 57/ 599 (9·5) 67/ 593 (11·3) 124/1192 (10·4)     
          
  Month 6 (Unadjusted)        
    0 56/ 607 (9·2) 55/ 605 (9·1) 111/1212 (9·2) 1·00 0·82 1·22 1·00 
    1 170/ 607 (28·0) 183/ 605 (30·2) 353/1212 (29·1)     
    2 96/ 607 (15·8) 80/ 605 (13·2) 176/1212 (14·5)     
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Outcome 
Intervention 
(N=623) 
Usual care 
(N=627) 
Total 
(N=1250) 
Odds 
Ratio 
95%  
Confidence intervals p-value* 
 n/N (%) n/N (%) n/N (%)  
    3 120/ 607 (19·8) 123/ 605 (20·3) 243/1212 (20·0)     
    4 82/ 607 (13·5) 65/ 605 (10·7) 147/1212 (12·1)     
    5 11/ 607 (1·8) 13/ 605 (2·1) 24/1212 (2·0)     
    6 72/ 607 (11·9) 86/ 605 (14·2) 158/1212 (13·0)     
  Month 6 (Adjusted)        
    0 56/ 606 (9·2) 55/ 605 (9·1) 111/1211 (9·2) 1·03 0·84 1·27 0·75 
    1 170/ 606 (28·1) 183/ 605 (30·2) 353/1211 (29·1)     
    2 96/ 606 (15·8) 80/ 605 (13·2) 176/1211 (14·5)     
    3 120/ 606 (19·8) 123/ 605 (20·3) 243/1211 (20·1)     
    4 81/ 606 (13·4) 65/ 605 (10·7) 146/1211 (12·1)     
    5 11/ 606 (1·8) 13/ 605 (2·1) 24/1211 (2·0)     
    6 72/ 606 (11·9) 86/ 605 (14·2) 158/1211 (13·0)     
Sensitivity analysis for month 6*        
 Death or disability        
  Month 6 (Unadjusted) 292/ 615 (47·5) 291/ 611 (47·6) 583/1226 (47·6) 0·99 0·79 1·24 0·96 
  Month 6 (Adjusted) 291/ 614 (47·4) 291/ 611 (47·6) 582/1225 (47·5) 1·03 0·80 1·31 0·83 
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Outcome 
Intervention 
(N=623) 
Usual care 
(N=627) 
Total 
(N=1250) 
Odds 
Ratio 
95%  
Confidence intervals p-value* 
 n/N (%) n/N (%) n/N (%)  
 Ordinal analysis        
  Month 6 (Unadjusted)        
    0 56/ 615 (9·1) 55/ 611 (9·0) 111/1226 (9·1) 1·01 0·83 1·23 0·95 
    1 170/ 615 (27·6) 184/ 611 (30·1) 354/1226 (28·9)     
    2 97/ 615 (15·8) 81/ 611 (13·3) 178/1226 (14·5)     
    3 123/ 615 (20·0) 124/ 611 (20·3) 247/1226 (20·1)     
    4 86/ 615 (14·0) 66/ 611 (10·8) 152/1226 (12·4)     
    5 11/ 615 (1·8) 15/ 611 (2·5) 26/1226 (2·1)     
    6 72/ 615 (11·7) 86/ 611 (14·1) 158/1226 (12·9)     
  Month 6 (Adjusted)        
    0 56/ 614 (9·1) 55/ 611 (9·0) 111/1225 (9·1) 1·03 0·84 1·26 0·77 
    1 170/ 614 (27·7) 184/ 611 (30·1) 354/1225 (28·9)     
    2 97/ 614 (15·8) 81/ 611 (13·3) 178/1225 (14·5)     
    3 123/ 614 (20·0) 124/ 611 (20·3) 247/1225 (20·2)     
    4 85/ 614 (13·8) 66/ 611 (10·8) 151/1225 (12·3)     
    5 11/ 614 (1·8) 15/ 611 (2·5) 26/1225 (2·1)     
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Outcome 
Intervention 
(N=623) 
Usual care 
(N=627) 
Total 
(N=1250) 
Odds 
Ratio 
95%  
Confidence intervals p-value* 
 n/N (%) n/N (%) n/N (%)  
    6 72/ 614 (11·7) 86/ 611 (14·1) 158/1225 (12·9)     
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   Figure 2:  Primary outcome of mRS 
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Table 3: Analysis of secondary outcomes at Month 3 and Month 6 
 
 Month 3 Month 6 
 Intervention Control P-value Intervention Control P-value 
Complete recovery from stroke 72/546 (13·2) 78/530 (14·7) 0·55* 133/534 (24·9) 142/514 (27·6) 0·28* 
 
Need help for everyday activities 332/543 (61·1) 320/528 (60·6) 0·60* 266/533 (49·9) 245/514 (47·7) 0·17* 
 
Place of residence 0·81†  0·92† 
   Same as before stroke 516/543 (95·0) 500/528 (94·7)  502/533 (94·2) 483/512 (94·3)  
   Other 27/543 (5·0) 28/528 (5·3)  31/533 (5·8) 29/512 (5·7)  
      In another hospital since admission for stroke 1/27 (3·7) 1/28 (3·6)  1/31 (3·2) 0/29 (0·0)  
      In family/ friends` home 17/27 (63·0) 14/28 (50·0)  16/31 (51·6) 11/29 (37·9)  
      In same hospital since admission for stroke    0/31 (0·0) 1/29 (3·4)  
      Other dwelling place 9/27 (33·3) 13/28 (46·4)  14/31 (45·2) 17/29 (58·6)  
       
Barthel Index total score   0·41‡   0·74‡ 
       
   N   Mean (SD) 543   76·1 (25·24) 525   74·8 (26·05)  533   82·1 (23·09) 512   82·6 (23·19)  
   Median (interquartile range)   85 (60 to100) 85 (60 to 100)  95 (70 to 100)    95 (70 to 100)  
   min   max 0   100 0   100  0   100 0   100  
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 Month 3 Month 6 
Caregiver burden total score   0·21‡   0·52‡ 
       
   N   Mean (SD) 543   30·9 (10·70) 524   31·7 (11·38)  532   28·9 (10·01) 511   29·3 (10·85)  
   Median (interquartile range) 27 (22 to 35) 29 (22 to 37)  25 21 to 33 25 (21 to 33)  
   min   max 21   73 21   80  21   77 21   81  
Nottingham Extended ADL Scale       
Total score   0·43†   0·86† 
   N   Mean (SD) 537   27·1 (17·21) 523   26·3 (17·31)  527   31·0 (17·67) 509   31·2 (17·52)  
   Median (interquartile range) 27 (12 to 40) 25 (11 to 40)  31 (16 to 45) 32 (17 to 44)  
   min   max 0   66 0   66  0   66 0   66  
WHOQoL-BREF       
   Physical health   0·96‡   0·63‡ 
      N   Mean (SD) 534   51·2 (12·65) 521   51·3 (12·28)  525   54·3 (12·06) 509   54·7 (12·11)  
      Median (interquartile range) 56 (44 to 63) 56 (44 to 63)  56 (44 to 63) 56 (44 to 63)  
      min   max 13   81 6   81  13   94 19   100  
   Psychological   0·99‡   0·17‡ 
      N   Mean (SD) 534   49·2 (15·16) 521   49·3 (14·99)  525   52·1 (15·09) 509   53·4 (14·63)  
      Median (interquartile range) 50 38 to 56) 50 (38 to 63)  56 (44 to 63) 56 (44 to 63)  
      min   max 6   100 6   94  0   94 6   88  
   Social relationship   0·42‡   0·45‡ 
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 Month 3 Month 6 
      N   Mean (SD) 529   60·8 (17·21) 519   60·0 (16·89)  523   63·0 (17·41) 509   62·2 (18·43)  
      Median (interquartile range) 69 (50 to 75) 56 (50 to 69)  69 (50 to 75) 69 (50 to 75)  
      min   max 0   100 0   100  0   100 0   100  
   Environment   0·61‡   0·76‡ 
      N   Mean (SD) 534   65·3 (14·70) 521   64·8 (15·78)  525   67·8 (15·69) 509   68·1 (15·95)  
      Median (interquartile range) 69 (56 to 75) 63 (56 to 75)  69 (56 to 75) 69 (56 to 81)  
      min   max 19   100 13   100  19   100 19   100  
   Quality of life   0·41*   0·52* 
      Very poor 21/535 (3·9) 34/521 (6·5)  17/526 (3·2) 17/509 (3·3)  
      Poor 97/535 (18·1) 86/521 (16·5)  77/526 (14·6) 72/509 (14·1)  
      Neither poor nor good 176/535 (32·9) 167/521 (32·1)  115/526 (21·9) 105/509 (20·6)  
      Good 225/535 (42·1) 217/521 (41·7)  284/526 (54·0) 268/509 (52·7)  
      Very good 16/535 (3·0) 17/521 (3·3)  33/526 (6·3) 47/509 (9·2)  
   Satisfaction with health   0·31*   0·65* 
      Very dissatisfied 24/535 (4·5) 17/521 (3·3)  18/526 (3·4) 16/509 (3·1)  
      Dissatisfied 142/535 (26·5) 123/521 (23·6)  111/526 (21·1) 92/509 (18·1)  
      Neither satisfied nor dissatisfied 152/535 (28·4) 156/521 (29·9)  105/526 (20·0) 104/509 (20·4)  
      Satisfied 204/535 (38·1) 203/521 (39·0)  257/526 (48·9) 254/509 (49·9)  
      Very satisfied 13/535 (2·4) 22/521 (4·2)  35/526 (6·7) 43/509 (8·4)  
EQ-5D       
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 Month 3 Month 6 
   Mobility   0·37*   0·32* 
      I have no problems in walking 256/539 (47·5) 226/523 (43·2)  292/529 (55·2) 282/510 (55·3)  
      I have some problems in walking 235/539 (43·6) 247/523 (47·2)  201/529 (38·0) 204/510 (40·0)  
      I am confined to bed 48/539 (8·9) 50/523 (9·6)  36/529 (6·8) 24/510 (4·7)  
   Self-care   0·52*   0·75* 
      I have no problems with self-care 235/539 (43·6) 212/523 (40·5)  278/529 (52·6) 280/510 (54·9)  
      I have some problems bathing or dressing myself 199/539 (36·9) 197/523 (37·7)  176/529 (33·3) 162/510 (31·8)  
      I am unable to bathe or dress myself 105/539 (19·5) 114/523 (21·8)  75/529 (14·2) 68/510 (13·3)  
   Usual activities   0·95*   0·59* 
      I have no problems in performing my usual activities 185/538 (34·4) 175/523 (33·5)  227/529 (42·9) 232/510 (45·5)  
      I have some problems in performing my usual activities 210/538 (39·0) 206/523 (39·4)  211/529 (39·9) 188/510 (36·9)  
      I am unable to perform my usual activities 143/538 (26·6) 142/523 (27·2)  91/529 (17·2) 90/510 (17·6)  
   Pain/discomfort   0·70*   0·64* 
      I have no pain or discomfort 228/538 (42·4) 210/523 (40·2)  270/529 (51·0) 273/510 (53·5)  
      I have moderate pain or discomfort 270/538 (50·2) 269/523 (51·4)  231/529 (43·7) 208/510 (40·8)  
      I have extreme pain or discomfort 40/538 (7·4) 44/523 (8·4)  28/529 (5·3) 29/510 (5·7)  
   Anxiety/Depression   0·70*   0·44* 
      I am not anxious or depressed 229/538 (42·6) 212/523 (40·5)  265/529 (50·1) 257/510 (50·4)  
      I am moderately anxious or depressed 266/538 (49·4) 272/523 (52·0)  238/529 (45·0) 219/510 (42·9)  
      I am extremely anxious or depressed 43/538 (8·0) 39/523 (7·5)  26/529 (4·9) 34/510 (6·7)  
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 Month 3 Month 6 
   Overall health state   0·68‡   0·18‡ 
      N   Mean (SD) 539   63·2 (21·21) 523   63·8 (20·82)  529   70·1 (20·36) 510   71·8 (20·40)  
      Median (interquartile range) 65 (50 to 80) 65 (50 to 80)  70 (55 to 90) 75 (60 to 90)  
      min   max 3   100 0   100  0   100 0   100  
Hospital Anxiety and Depression Scale       
Patient       
   HADS Total score   0·67‡   0·90‡ 
      N   Mean (SD) 536   11·3 (8·35) 520   11·5 (8·72)  527   9·0 (7·81) 509   9·1 (8·64)  
      Median (interquartile range) 10 (5 to 17) 10 (4 to 18)   7 (3 to 14) 7 (2 to 13)  
      min   max 0   39 0   39  0   38 0   42  
   HADS Anxiety score   0·57‡   0·91‡ 
      N   Mean (SD) 536   4·8 (4·01) 520   4·9 (4·36)  527   3·7 (3·74) 509   3·7 (4·19)  
      Median (interquartile range) 4 (1 to 7) 4 (1 to 8)  3 (0 to 6) 2 (0 to 6)  
      min   max 0   18 0   18  0   18 0   21  
      Score >= 8 122/536 (22·8) 138/520 (26·5) 0·15* 84/527 (15·9) 83/509 (16·3) 0·87* 
   HADS Depression score   0·79‡   0·91‡ 
      N   Mean (SD) 536   6·5 (4·94) 520   6·6 (4·99)  527   5·3 (4·64) 509   5·3 (4·96)  
      Median (interquartile range) 6 (2 to 10) 6 (2 to 10)   4 (2 to 8) 4 (1 to 8)  
      min   max 0   21 0   21  0   21 0   21  
      Score >= 8 197/536 (36·8) 198/520 (38·1) 0·66* 145/527 (27·5) 141/509 (27·7) 0·95* 
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 Month 3 Month 6 
Caregiver       
   HADS Total score   0·62‡   0·86‡ 
      N   Mean (SD) 546   7·5 (7·52) 527   7·7 (7·88)  532   5·5 (6·68) 511   5·5 (6·80)  
      Median (interquartile range) 5 (2 to 12) 5 (1 to 12)   3 (0 to 9) 3 (0 to 8)  
      min   max 0   42 0   39  0   36 0   42  
   HADS Anxiety score   0·67‡   0·91‡ 
      N   Mean (SD) 546   3·7 (3·86) 527   3·8 (4·17)  532   2·7 (3·40) 511   2·6 (3·51)  
      Median (interquartile range) 2 (0 to 6)  2 (0 to 6)  1 (0 to 4) 1 (0 to 4)  
      min   max 0   21 0   20  0   16 0   21  
      Score >= 8 83/546 (15·2) 96/527 (18·2) 0·19* 55/532 (10·3) 50/511 (9·8) 0·77* 
   HADS Depression score   0·61‡   0·82‡ 
      N   Mean (SD) 546   3·8 (4·17) 527   3·9 (4·16)  532   2·9 (3·69) 511   2·8 (3·60)  
      Median (interquartile range) 3 (0 to 6) 3 (0 to 6)  1 (0 to 5) 2 (0 to 5)  
      min   max 0   21 0   21  0   21 0   21  
      Score >= 8 100/546 (18·3) 100/527 (19·0) 0·78* 68/532 (12·8) 56/511 (11·0) 0·36* 
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